Search results for "Hematologi"

showing 10 items of 194 documents

Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplan…

2004

International audience; Background. Isolated case reports have shown that recipients of allogeneic hematopoietic stem cell transplants ( HSCTs) who develop toxoplasmosis may have circulating Toxoplasma gondii DNA in peripheral blood before the onset of clinical symptoms. Methods. We prospectively studied 106 T. gondii - seropositive adult recipients of HSCTs for the incidence of reactivation of toxoplasmosis in the first 6 months after transplantation. Toxoplasmosis infection ( TI) was defined by a positive result of polymerase chain reaction ( PCR) of peripheral blood specimens, whereas toxoplasmosis disease ( TD) was defined as an invasive infection. Results. The incidence of TI was 16% (…

AdultMicrobiology (medical)POLYMERASE-CHAIN-REACTIONmedicine.medical_treatment[SDV]Life Sciences [q-bio]Hematopoietic stem cell transplantationPolymerase Chain ReactionParasite loadCYTOMEGALOVIRUS-INFECTIONBlood cell03 medical and health sciencesIMMUNE RECONSTITUTION0302 clinical medicinemedicineAnimalsHumansTransplantation Homologous030212 general & internal medicineREAL-TIME PCR0303 health sciencesHematologic Testsbiology030306 microbiologybusiness.industryIncidence (epidemiology)Toxoplasma gondiiDNA Protozoanbiology.organism_classificationmedicine.diseaseBONE-MARROW-TRANSPLANTATIONPREEMPTIVE THERAPYToxoplasmosis3. Good healthTransplantationRECIPIENTSInfectious DiseasesReal-time polymerase chain reactionmedicine.anatomical_structureImmunologySTATISTICAL-METHODSTRANSFER HYBRIDIZATION PROBESbusinessToxoplasmaToxoplasmosisStem Cell Transplantation
researchProduct

Relevance of new recommendations on routine antenatal prevention of rhesus immunization: an appraisal based on a retrospective analysis of all cases …

2008

Abstract Objective To assess the potential impact of new guidelines recommending routine antenatal prophylaxis at 28 weeks of pregnancy on incidence, consequences and cost of rhesus immunization. Study design All rhesus immunizations of 224,500 ongoing pregnancies in two neighbouring administrative areas in France between 2000 and 2006 were enrolled in this retrospective study. To determine the aetiology of immunization and to specify when sensitization occurred, we searched sensitizing events between the last negative and the first positive red-cell antibody test results. Perinatal consequences and costing were also analyzed. Results From 138 rhesus negative women bearing anti-D antibodies…

AdultPediatricsmedicine.medical_specialtyAdolescentCost effectivenessCost-Benefit AnalysisRho(D) Immune GlobulinPopulationRh IsoimmunizationIsoantibodiesPregnancyIntensive caremedicineHumanseducationRetrospective StudiesPregnancyeducation.field_of_studyRh-Hr Blood-Group Systembusiness.industryIncidence (epidemiology)Pregnancy Complications HematologicInfant NewbornObstetrics and GynecologyRetrospective cohort studymedicine.diseaseFetomaternal TransfusionVaccinationReproductive MedicineImmunizationFemaleFrancebusinessEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

Haemocoagulative modifications correlated with pregnancy

2006

The aim of this paper was to establish the physiologic changes in the coagulation and fibrinolytic systems during normal pregnancy.One-hundred and twenty normal pregnant women were investigated in a longitudinal study involving 3 measurements: blood samples were collected at 12, 24 and 36 weeks of gestation and were assayed for prothrombin time, antithrombin III (ATIII) activity, protein C activity, protein S (PS) activity, prothrombin fragments 1+2, type 1 plasminogen activator inhibitor activity, tissue plasminogen activator antigen, plasminogen, activated protein C resistance, factors VII and VIII levels and D dimer. Student t-test, one way analysis of variance (ANOVA) and Fisher test we…

AdultPregnancyFibrinolysisPregnancy Complications HematologicHumansFibrinolysiFemaleLongitudinal StudieLongitudinal StudiesBlood CoagulationHuman
researchProduct

Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myelo…

2022

Post-transplant cyclophosphamide (PTCy) has emerged as a promising graft-versus-host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no studies have reported the efficacy of a GvHD prophylaxis based on PTCy with sirolimus (Sir-PTCy) in patients with acute myeloid leukemia (AML). In this retrospective study, we analyze the use of sirolimus in combination with PTCy, with or without mycophenolate mofetil (MMF), on 242 consecutive adult patients with AML undergoing a myeloablative first allo-HSCT from different donor types, in three European centers between January 2017 and December 2020. Seventy-seven (32%) patients received allo-HSCT from…

AdultSirolimusTransplantationBLOODTransplantation ConditioningCONDITIONING INTENSITYGVHD PROPHYLAXISHematopoietic Stem Cell TransplantationGraft vs Host Disease1ST COMPLETE REMISSIONHematologyMycophenolic AcidOPEN-LABELDIAGNOSISPatologiaHEMATOLOGIC MALIGNANCIESEUROPEAN-SOCIETYLeukemia Myeloid AcuteRISK INDEXHumansMARROW-TRANSPLANTATIONUnrelated DonorsCyclophosphamideRetrospective StudiesBone marrow transplantation
researchProduct

Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomi…

2012

Background and objective: Thrombopoietin receptor (TPOr) agonists (romiplostim and eltrombopag) are a new approach for the treatment of thrombocytopenia-associated conditions. They promote megakaryocyte differentiation, proliferation and platelet production. In the European Union, both are orphan drugs with an indication restricted to splenectomized immune thrombocytopenic purpura patients who are refractory to other treatments. Due to increasing platelet counts, these drugs may represent a risk for thromboembolic complications. We analyzed whether TPOr agonists affect thromboembolisms occurrence in adult thrombocytopenic patients. Materials and methods: We conducted a systematic review and…

Adultmedicine.medical_specialtyMegakaryocyte differentiationRecombinant Fusion ProteinsEltrombopagReceptors FcBenzoateslaw.inventionchemistry.chemical_compoundRandomized controlled triallawRisk FactorsInternal medicineHematologic AgentsThromboembolismmedicinemedia_common.cataloged_instanceHumansEuropean unionmedia_commonRandomized Controlled Trials as TopicRomiplostimbusiness.industryGeneral MedicineNumber needed to harmThrombocytopeniaSurgeryHydrazineschemistryThrombopoietinMeta-analysisRelative riskPyrazolesbusinessReceptors Thrombopoietinmedicine.drugMedicina clinica
researchProduct

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a pa…

2020

Summary The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be general…

Adultmedicine.medical_specialtyMyeloidCoronavirus disease 2019 (COVID-19)Pneumonia ViralPopulationCovid 19 hematological neoplasia managementMEDLINEArticleResource AllocationBetacoronavirus03 medical and health sciences0302 clinical medicinePandemicHumansMedicineDisease management (health)Intensive care medicineeducationExpert TestimonyPandemicsInfection Controleducation.field_of_studyLeukemiaMyeloproliferative DisordersSARS-CoV-2business.industryPublic healthCOVID-19Disease ManagementHematology3. Good healthClinical trialmedicine.anatomical_structure030220 oncology & carcinogenesisPractice Guidelines as TopicCoronavirus Infectionsbusiness030215 immunology
researchProduct

Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Trans…

2020

In this prospective randomized study, we compared the outcomes of single-unit umbilical cord blood transplantation (UCBT) and unmanipulated haploidentical stem cell transplantation (haplo-SCT) with post-transplantation cyclophosphamide (PTCy) in adults with hematologic malignancies. All patients received a myeloablative conditioning (MAC) regimen consisting of thiotepa, busulfan, and fludarabine, with antithymocyte globulin (ATG) added for UCBT recipients. Nineteen patients were randomized to UCBT and the other 26 to haplo-HSCT. Four patients (15%) allocated to the haplo-HSCT arm lacked a suitable donor and were crossed over to the UCBT arm. Finally, 23 underwent UCBT and 22 underwent haplo…

Adultmedicine.medical_specialtyendocrine systemHematologic malignancyTransplantation ConditioningHaploidentical transplantationGraft vs Host DiseaseContext (language use)ThioTEPAGastroenterologyMAC Regimen03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCumulative incidenceProspective StudiesTransplantationAllogeneic stem cell transplantation clinical trial Alternative donor transplantation Haploidentical transplantation Hematologic malignancy Umbilical cord blood transplantationUmbilical cord blood transplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyAlternative donor transplantationFludarabineTransplantationRegimenAllogeneic stem cell transplantation clinical trialsurgical procedures operative030220 oncology & carcinogenesisHematologic NeoplasmsCord Blood Stem Cell TransplantationNeoplasm Recurrence LocalbusinessBusulfan030215 immunologymedicine.drug
researchProduct

Specific challenges in end-of-life care for patients with hematological malignancies.

2019

Purpose of review The disease-related burden of patients with hematological malignancies is comparable with patients suffering from solid tumors. Palliative care offers relief from suffering independent of type of disease and prognosis. The prevalence of hematological malignancies is expected to increase in the next 20 years because of better therapeutic options with longer survival and because of the aging population. However, patients with hematological malignancies are underrepresented in palliative care as these diseases are associated with special care needs and prognostic uncertainty, which differ from the unambiguity of terminally ill patients with solid tumors. This review describes…

Advance care planningmedicine.medical_specialtyPalliative caremedicine.medical_treatmentHealth StatusMEDLINEHematopoietic stem cell transplantationDiseaseComorbidityCritical Care and Intensive Care Medicine03 medical and health sciencesAdvance Care Planning0302 clinical medicineMedicineHumans030212 general & internal medicineIntensive care medicineQualitative ResearchTerminal CareOncology (nursing)business.industryPalliative CareHematopoietic Stem Cell TransplantationUncertaintyGeneral Medicinemedicine.diseasePrognosisComorbidity3. Good health030228 respiratory systemOncologyCaregiversHematologic NeoplasmsInterdisciplinary CommunicationbusinessEnd-of-life careQualitative researchCurrent opinion in supportive and palliative care
researchProduct

Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.

2015

Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types and participate in physiological and pathophysiological processes. EVs mediate intercellular communication as cell-derived extracellular signalling organelles that transmit specific information from their cell of origin to their target cells. As a result of these properties, EVs of defined cell types may serve as novel tools for various therapeutic approaches, including (a) anti-tumour therapy, (b) pathogen vaccination, (c) immune-modulatory and regenerative therapies and (d) drug delivery. The translation of EVs into clinical therapies requires the categorization of EV-based therapeutics …

Bioquímica clínicaMedizinISCHEMIA-REPERFUSION INJURYBioinformaticsimmunology; neurobiology; haematology; stem cells; tissue regeneration; tumour vaccination; regulationimmunology0302 clinical medicineClinical trialsClinical investigationVERSUS-HOST-DISEASEMedicine and Health SciencesFIELD-FLOW FRACTIONATIONMedicineImmunologiahaematology; immunology; neurobiology; regulation; stem cells; tissue regeneration; tumour vaccinationmedia_common0303 health scienceslcsh:CytologyOUTER-MEMBRANE VESICLESneurobiologyregulationHematologyBiologia experimental3. Good healthTUMOR-DERIVED EXOSOMES030220 oncology & carcinogenesistumour vaccinationDrug deliveryhaematologyPosition PaperCèl·lules mareNeurobiologiaHistologyMedicina InvestigacióCèl·lulesNANOPARTICLE TRACKING ANALYSIStissue regenerationExtracellular vesiclesMESENCHYMAL STEM-CELLS03 medical and health sciencesstem cellsJournal Articlemedia_common.cataloged_instanceREGULATORY T-CELLSEuropean unionlcsh:QH573-671ENDOTHELIAL PROGENITOR CELLSHematologia030304 developmental biologybusiness.industryCell BiologyMicrovesiclesClinical trialPosition paperPharmaceutical manufacturingUMBILICAL-CORD BLOODbusinessNeuroscienceAssaigs clínics
researchProduct

Remodelling of biological parameters during human ageing: evidence for complex regulation in longevity and in type 2 diabetes.

2013

Factor structure analyses have revealed the presence of specific biological system markers in healthy humans and diseases. However, this type of approach in very old persons and in type 2 diabetes (T2DM) is lacking. A total sample of 2,137 Italians consisted of two groups: 1,604 healthy and 533 with T2DM. Age (years) was categorized as adults (≤65), old (66-85), oldest old (>85-98) and centenarians (≥99). Specific biomarkers of routine haematological and biochemical testing were tested across each age group. Exploratory factorial analysis (EFA) by principal component method with Varimax rotation was used to identify factors including related variables. Structural equation modelling (SEM) wa…

Blood GlucoseMaleGerontologyAgingAgeing Diabetes longevityPhysiologyType 2 diabetescentenarianHemoglobinsLeukocyte CountAged 80 and overPrincipal Component AnalysisHematologic TestsbiologyGeneral MedicineMiddle AgedExplained variationExploratory factor analysisexploratory factor analysiC-Reactive ProteinCholesteroldiabetic patientsItalyFemaleAnalysis of varianceAdultSTRUCTURAL EQUATION MODELINGAdolescentVarimax rotationLongevityAGEINGArticlemedicineHumansTriglyceridesAgedSettore MED/04 - Patologia GeneraleAnalysis of VarianceChi-Square DistributionC-reactive proteinFibrinogenmedicine.diseaseDiabetes Mellitus Type 2Ageingbiology.proteinGeriatrics and GerontologyFactor Analysis StatisticalChi-squared distributionBiomarkers
researchProduct